2022 Anticancer research

The First Prognostic Tool to Estimate the Risk of Late Grade >/=3 Xerostomia in Patients Irradiated for Head-and-Neck Cancer.

, , , , , , , ,

Anticancer research Vol. 42 (6) : 3035-3039 • Jun 2022

BACKGROUND/AIM: Xerostomia is a serious complication following radiotherapy of head-and-neck cancers. A prognostic tool was developed for estimating its risk. PATIENTS AND METHODS: In our previous study, age, tumor site, bilateral lymph node involvement, definitive radiotherapy, and addition of systemic therapies showed significant associations with grade >/=3 late xerostomia or trends. In additional analyses, mean radiation dose to ipsilateral parotid gland was significant (p=0.011). These six factors were included in the prognostic tool. Scoring points of 0 (lower risk) or 1 (higher risk) were assigned to each factor and added for each patient. RESULTS: Patient scores ranged between 0 and 6; Grade >/=3 xerostomia rates were 0%, 8%, 24%, 26%, 25%, 42%, and 100%, respectively. Three groups were designed (0-1, 2-4, and 5-6 points) with grade >/=3 xerostomia rates of 5%, 25%, and 50%, respectively (p<0.001). CONCLUSION: This new tool helps estimating the risk of radiation-induced grade >/=3 xerostomia. It can support physicians and other medical staff members during treatment planning.

No clinical trial protocols linked to this paper

Clinical trials are automatically linked when NCT numbers are found in the paper's title or abstract.
PICO Elements

No PICO elements extracted yet. Click "Extract PICO" to analyze this paper.

Paper Details
MeSH Terms
Associated Data

No associated datasets or code repositories found for this paper.

Related Papers

Related paper suggestions will be available in future updates.